Notification of approval of agreement with GlaxoSmithKline regarding the listing of lamotrigine (Lamictal) on the Pharmaceutical Schedule

Medicines

Decision

PHARMAC is pleased to announce that PHARMAC’s Board has approved an agreement with GlaxoSmithKline NZ Ltd amending the terms of listing of Lamictal (lamotrigine dispersible tablets) in Sections B and H of the Pharmaceutical Schedule from 1 July 2007.

This means that:

  • The price and subsidy for all strengths of Lamotrigine (Lamictal) dispersible tablets except the 5 mg strength listed in Section B of the Pharmaceutical Schedule will be decreased from 1 July 2007 as follows (prices expressed ex-manufacturer, excl. GST):
    Pharmaceutical Brand Form Strength Pack size Current price & subsidy New price & subsidy
    Lamotrigine Lamictal Tablet 5 mg 30 $9.64 $9.64
    Lamotrigine Lamictal Tablet 25 mg 56 $51.07 $29.09
    Lamotrigine Lamictal Tablet 50 mg 56 $86.82 $47.89
    Lamotrigine Lamictal Tablet 100 mg 56 $149.81 $79.16
  • A new 2 mg strength of Lamictal will be listed in Section B of the Pharmaceutical Schedule from 1 July 2007 at a price and subsidy of $6.74 per 30 tablets (ex-manufacturer, excluding GST).
  • Lamictal will be listed in Section B of the Pharmaceutical Schedule without the requirement for Special Authority for subsidy from 1 July 2007.
  • Lamictal dispersible tablets will be listed in Part II of Section H of the Pharmaceutical Schedule from 1 July 2007 at the following prices (ex-manufacturer, excluding GST):
    Pharmaceutical Brand Form Strength Pack Size Price
    Lamotrigine Lamictal Tablet 2 mg 30 $6.74
    Lamotrigine Lamictal Tablet 5 mg 30 $9.64
    Lamotrigine Lamictal Tablet 25 mg 56 $29.09
    Lamotrigine Lamictal Tablet 50 mg 56 $47.89
    Lamotrigine Lamictal Tablet 100 mg 56 $79.16

If you have any queries about this listing please contact the PHARMAC helpline on 0800 66 00 50 (9am to 4pm weekdays).